Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1984 1
1985 1
1990 1
1997 1
2001 1
2006 2
2008 2
2009 1
2010 1
2011 4
2012 2
2013 1
2014 1
2015 1
2016 3
2017 5
2018 3
2019 2
2020 7
2021 7
2022 3
2023 3
2024 2

Text availability

Article attribute

Article type

Publication date

Search Results

46 results

Results by year

Filters applied: . Clear all
Quoted phrase not found in phrase index: "Recurrent AL Amyloidosis"
Page 1
Recurrent Glomerular Disease after Kidney Transplantation: Diagnostic and Management Dilemmas.
Uffing A, Hullekes F, Riella LV, Hogan JJ. Uffing A, et al. Clin J Am Soc Nephrol. 2021 Nov;16(11):1730-1742. doi: 10.2215/CJN.00280121. Epub 2021 Oct 22. Clin J Am Soc Nephrol. 2021. PMID: 34686531 Free PMC article.
Recurrent glomerular disease after kidney transplant remains an important cause of allograft failure. ...In this review, we focus on specific clinical dilemmas encountered by physicians in managing recurrent glomerular disease by highlighting new insights into the u …
Recurrent glomerular disease after kidney transplant remains an important cause of allograft failure. ...In this review, we focus on …
Renal transplant outcomes in amyloidosis.
Law S, Cohen O, Lachmann HJ, Rezk T, Gilbertson JA, Rowczenio D, Wechalekar AD, Hawkins PN, Motallebzadeh R, Gillmore JD. Law S, et al. Nephrol Dial Transplant. 2021 Jan 25;36(2):355-365. doi: 10.1093/ndt/gfaa293. Nephrol Dial Transplant. 2021. PMID: 33439995
BACKGROUND: Outcomes after renal transplantation have traditionally been poor in systemic amyloid A (AA) amyloidosis and systemic light chain (AL) amyloidosis, with high mortality and frequent recurrent disease. ...CONCLUSIONS: Renal tran …
BACKGROUND: Outcomes after renal transplantation have traditionally been poor in systemic amyloid A (AA) amyloidosis and systemic …
Presentation and outcome with second-line treatment in AL amyloidosis previously sensitive to nontransplant therapies.
Palladini G, Milani P, Foli A, Basset M, Russo F, Perlini S, Merlini G. Palladini G, et al. Blood. 2018 Feb 1;131(5):525-532. doi: 10.1182/blood-2017-04-780544. Epub 2017 Nov 3. Blood. 2018. PMID: 29101236 Free article.
The management of light chain (AL) amyloidosis has improved in recent years thanks to accurate biomarker-based staging systems and response criteria and availability of novel effective therapies. ...Patients who had a "high-risk dFLC progression," whic …
The management of light chain (AL) amyloidosis has improved in recent years thanks to accurate biomarker-based s …
Amyloidosis in the head and neck: CT findings with clinicopathological correlation.
Takumi K, Staziaki PV, Hito R, Nadgir RN, Berk JL, Andreu-Arasa VC, Chavez W, Sakai O. Takumi K, et al. Eur J Radiol. 2020 Jul;128:109034. doi: 10.1016/j.ejrad.2020.109034. Epub 2020 Apr 30. Eur J Radiol. 2020. PMID: 32438260
RESULTS: Localized disease (83.8%, 67/80) was most common with AL type (97.6%, 41/42) representing nearly all cases of head and neck amyloidosis. ...Airway wall thickness in patients who required repeated surgical treatment was significantly greater than in patients …
RESULTS: Localized disease (83.8%, 67/80) was most common with AL type (97.6%, 41/42) representing nearly all cases of head and neck …
Periocular and orbital amyloidosis: clinical characteristics, management, and outcome.
Leibovitch I, Selva D, Goldberg RA, Sullivan TJ, Saeed P, Davis G, McCann JD, McNab A, Rootman J. Leibovitch I, et al. Ophthalmology. 2006 Sep;113(9):1657-64. doi: 10.1016/j.ophtha.2006.03.052. Epub 2006 Jul 7. Ophthalmology. 2006. PMID: 16828514
Immunohistochemistry in 7 patients showed B cells or plasma cells producing monoclonal immunoglobulin chains that were deposited as amyloid light chains. Only 1 patient was diagnosed with systemic amyloid light chain amyloidosis. Treatment modalities w …
Immunohistochemistry in 7 patients showed B cells or plasma cells producing monoclonal immunoglobulin chains that were deposited as a …
Predictors of hematologic response and survival with stem cell transplantation in AL amyloidosis: A 25-year longitudinal study.
Gustine JN, Staron A, Szalat RE, Mendelson LM, Joshi T, Ruberg FL, Siddiqi O, Gopal DM, Edwards CV, Havasi A, Kaku M, Lau KHV, Berk JL, Sloan JM, Sanchorawala V. Gustine JN, et al. Am J Hematol. 2022 Sep;97(9):1189-1199. doi: 10.1002/ajh.26641. Epub 2022 Jul 5. Am J Hematol. 2022. PMID: 35731907 Free article.
High-dose melphalan and stem cell transplantation (HDM/SCT) is an effective treatment for selected patients with AL amyloidosis. We report the long-term outcomes of 648 patients with AL amyloidosis treated with HDM/SCT over 25 years. ...We conclude tha …
High-dose melphalan and stem cell transplantation (HDM/SCT) is an effective treatment for selected patients with AL amyloidosis …
Daratumumab for relapsed AL amyloidosis-When cumulative real-world data precedes clinical trials: A multisite study and systematic literature review.
Shragai T, Gatt M, Lavie N, Vaxman I, Tadmor T, Rouvio O, Zektser M, Horowitz N, Magen H, Ballan M, Suru C, Luttwak E, Levi S, Ziv-Baran T, Avivi I, Cohen YC. Shragai T, et al. Eur J Haematol. 2021 Feb;106(2):184-195. doi: 10.1111/ejh.13535. Epub 2020 Nov 9. Eur J Haematol. 2021. PMID: 33090552
OBJECTIVES: Patients with relapsed/refractory AL amyloidosis (RRAL) have poor prognosis, but emerging data shows promising results with the use daratumumab. ...RESULTS: Forty-nine patients, diagnosed between 1.1.2008 and 1.2.2018 were included; 27% also had multiple …
OBJECTIVES: Patients with relapsed/refractory AL amyloidosis (RRAL) have poor prognosis, but emerging data shows promising res …
Lenalidomide and dexamethasone in relapsed/refractory immunoglobulin light chain (AL) amyloidosis: results from a large cohort of patients with long follow-up.
Basset M, Kimmich CR, Schreck N, Krzykalla J, Dittrich T, Veelken K, Goldschmidt H, Seckinger A, Hose D, Jauch A, Müller-Tidow C, Benner A, Hegenbart U, Schönland SO. Basset M, et al. Br J Haematol. 2021 Oct;195(2):230-243. doi: 10.1111/bjh.17685. Epub 2021 Aug 3. Br J Haematol. 2021. PMID: 34341985
Lenalidomide and dexamethasone (RD) is a standard treatment in relapsed/refractory immunoglobulin light chain (AL) amyloidosis (RRAL). We retrospectively investigated toxicity, efficacy and prognostic markers in 260 patients with RRAL. ...VGHR r …
Lenalidomide and dexamethasone (RD) is a standard treatment in relapsed/refractory immunoglobulin light chain (AL …
High prevalence of recurrent nocturnal desaturations in systemic AL amyloidosis: a cross-sectional pilot study.
Mahmood S, Sovani M, Smith P, George L, Quarta CC, Sachchithanantham S, Fontana M, Whelan CJ, Lachmann HJ, Gillmore JD, Hawkins PN, Wechalekar AD. Mahmood S, et al. Sleep Med. 2017 Apr;32:191-197. doi: 10.1016/j.sleep.2016.11.021. Epub 2016 Dec 21. Sleep Med. 2017. PMID: 28366333
OBJECTIVES: Cardiac involvement and/or macroglossia with soft tissue deposits are risk factors for central sleep apnoea (CSA) and obstructive sleep apnoea (OSA), and common features of systemic AL amyloidosis. Little data exist on the occurrence of sleep-disordered …
OBJECTIVES: Cardiac involvement and/or macroglossia with soft tissue deposits are risk factors for central sleep apnoea (CSA) and obstructiv …
Measurable residual disease in multiple myeloma and light chain amyloidosis: more than meets the eye.
Vaxman I, Gertz MA. Vaxman I, et al. Leuk Lymphoma. 2021 Jul;62(7):1544-1553. doi: 10.1080/10428194.2021.1873320. Epub 2021 Jan 28. Leuk Lymphoma. 2021. PMID: 33508994 Review.
MRD is being incorporated as an endpoint in an increasing number of studies and had been repeatedly shown to be both a predictive marker of response to treatment and a prognostic marker for future relapse. ...This review aims to critically analyze the key MRD aspects inclu …
MRD is being incorporated as an endpoint in an increasing number of studies and had been repeatedly shown to be both a predictive mar …
46 results